English
Calliditas is focused on the development and commercialization of its lead product candidate Nefecon.
A potential treatment for patients with IgA nephropathy at risk of developing ESRD.
Calliditas shortlisted in two categories at the European Lifestars Awards: Post-IPO Equity Raise of the Year and Deal of the Year (<£500m)
On August 13, 2020, at 07:00 am CET, Calliditas Therapeutics (“Calliditas”) will publish its business update for the second quarter 2020.
